Cody L. Nesvick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cody L. Nesvick has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Lucas P. Carlstrom
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota
6 shared publications - Amanda Munoz-Casabella
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota
5 shared publications - Arthur E. Warrington
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota
5 shared publications - Cecile Riviere-Cazaux
Department of Neurological Surgery, Mayo Clinic , Rochester, MN
5 shared publications - Chao Dai
Predicine, Inc., Hayward, California
5 shared publications - David M. Routman
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
5 shared publications
Latest Publications
- Open Access
- 26 May 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 9 (21)
Stroke-like migraine attack after radiation therapy (SMART) syndrome in a pediatric patient with a ventriculoperitoneal shunt: illustrative case
BACKGROUND: Stroke-like migraine attack after radiation therapy (SMART) syndrome is a rare, episodic neurological condition characterized by headache and unilateral cortical deficits following remote cranial radiation therapy. It is more frequently reported in adults, while pediatric cases remain exceedingly rare due to the latency period between radiation therapy and onset, which can span years to decades. Diagnosis is challenging due to overlapping symptoms with conditions like ventriculoperitoneal shunt (VPS) malfunction. OBSERVATIONS: The authors report the case of an 11-year-old boy with SMART syndrome following radiation treatment for a resected pineal region nongerminomatous germ cell tumor and VPS placement. The patient presented with headache, vomiting, lethargy, and seizures, raising initial concern for shunt malfunction. MRI revealed left occipital and posterior temporal cortical FLAIR hyperintensity and abnormal leptomeningeal enhancement, consistent with SMART syndrome. Multidisciplinary evaluation ruled out shunt failure and tumor recurrence. A course of corticosteroids led to symptom resolution. A review of 15 pediatric cases highlights variability in latency, symptoms, and treatment, with most patients responding favorably. LESSONS: SMART syndrome, although rare, should be considered in pediatric patients with postradiation episodic neurological symptoms to avoid unnecessary interventions. Multidisciplinary collaboration is essential. Further studies are needed to establish standardized diagnostic and treatment protocols. https://thejns.org/doi/10.3171/CASE25189
- 26 May 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 9 (21)
Open AccessStroke-like migraine attack after radiation therapy (SMART) syndrome in a pediatric patient with a ventriculoperitoneal shunt: illustrative case
BACKGROUND: Stroke-like migraine attack after radiation therapy (SMART) syndrome is a rare, episodic neurological condition characterized by headache and unilateral cortical deficits following remote cranial radiation therapy. It is more frequently reported in adults, while pediatric cases remain exceedingly rare due to the latency period between radiation therapy and onset, which can span years to decades. Diagnosis is challenging due to overlapping symptoms with conditions like ventriculoperitoneal shunt (VPS) malfunction. OBSERVATIONS: The authors report the case of an 11-year-old boy with SMART syndrome following radiation treatment for a resected pineal region nongerminomatous germ cell tumor and VPS placement. The patient presented with headache, vomiting, lethargy, and seizures, raising initial concern for shunt malfunction. MRI revealed left occipital and posterior temporal cortical FLAIR hyperintensity and abnormal leptomeningeal enhancement, consistent with SMART syndrome. Multidisciplinary evaluation ruled out shunt failure and tumor recurrence. A course of corticosteroids led to symptom resolution. A review of 15 pediatric cases highlights variability in latency, symptoms, and treatment, with most patients responding favorably. LESSONS: SMART syndrome, although rare, should be considered in pediatric patients with postradiation episodic neurological symptoms to avoid unnecessary interventions. Multidisciplinary collaboration is essential. Further studies are needed to establish standardized diagnostic and treatment protocols. https://thejns.org/doi/10.3171/CASE25189
- Open Access
- 23 March 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (9) , 2445-2460
SWI/SNF complexes govern ontology-specific transcription factor function in MYC-subtype atypical teratoid rhabdoid tumor
Background: Atypical teratoid rhabdoid tumor (ATRT) is a deadly central nervous system embryonal tumor caused by loss of SMARCB1, a core subunit of SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complexes. SMARCB1-deficient cancers are defined by loss of cell differentiation-associated enhancers, but how SWI/SNF interacts with other arbiters of cell differentiation (specifically lineage-specific transcription factors [TFs]) remains poorly understood. Methods: We leveraged a multi-omics approach, patient-derived ATRT cells, and patient-derived orthotopic xenografts to investigate the interplay of SWI/SNF with lineage-specific TFs in a clinically relevant setting. Results: We observe that an activating protein 1 (AP-1)-dependent transcriptional regulatory network is lost in ATRT, and AP-1 and lineage-specific TFs TEAD1 and ZIC2 require SMARCB1 for enhancer binding. SMARCB1-dependent SWI/SNF integrates transcriptional functions of lineage-specific TFs into a core regulatory circuit that depends on the AP-1 subunit c-JUN, whose expression is determined by a SMARCB1-dependent super-enhancer that is lost in ATRT-MYC. In the absence of SMARCB1, lineage-specific TFs are sequestered to promoters, where they maintain core transcriptional programs necessary for cell survival. Targeting residual, promoter-proximal TF activity by a protein degrader of the SWI/SNF ATPase SMARCA4 or small-molecule inhibitors that indirectly inhibit AP-1 and TEAD activity abrogates expression of these networks, reducing cell viability in vitro and prolonging survival in an orthotopic patient-derived xenograft model. Conclusions: These results demonstrate SWI/SNF complexes are critical for lineage-specific TF binding and activity at both promoters and enhancers. In the context of ATRT, these findings reveal a previously underappreciated therapeutic vulnerability in targeting residual promoter-proximal TF function in ATRT.
- 23 March 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (9) , 2445-2460
Open AccessSWI/SNF complexes govern ontology-specific transcription factor function in MYC-subtype atypical teratoid rhabdoid tumor
Background: Atypical teratoid rhabdoid tumor (ATRT) is a deadly central nervous system embryonal tumor caused by loss of SMARCB1, a core subunit of SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complexes. SMARCB1-deficient cancers are defined by loss of cell differentiation-associated enhancers, but how SWI/SNF interacts with other arbiters of cell differentiation (specifically lineage-specific transcription factors [TFs]) remains poorly understood. Methods: We leveraged a multi-omics approach, patient-derived ATRT cells, and patient-derived orthotopic xenografts to investigate the interplay of SWI/SNF with lineage-specific TFs in a clinically relevant setting. Results: We observe that an activating protein 1 (AP-1)-dependent transcriptional regulatory network is lost in ATRT, and AP-1 and lineage-specific TFs TEAD1 and ZIC2 require SMARCB1 for enhancer binding. SMARCB1-dependent SWI/SNF integrates transcriptional functions of lineage-specific TFs into a core regulatory circuit that depends on the AP-1 subunit c-JUN, whose expression is determined by a SMARCB1-dependent super-enhancer that is lost in ATRT-MYC. In the absence of SMARCB1, lineage-specific TFs are sequestered to promoters, where they maintain core transcriptional programs necessary for cell survival. Targeting residual, promoter-proximal TF activity by a protein degrader of the SWI/SNF ATPase SMARCA4 or small-molecule inhibitors that indirectly inhibit AP-1 and TEAD activity abrogates expression of these networks, reducing cell viability in vitro and prolonging survival in an orthotopic patient-derived xenograft model. Conclusions: These results demonstrate SWI/SNF complexes are critical for lineage-specific TF binding and activity at both promoters and enhancers. In the context of ATRT, these findings reveal a previously underappreciated therapeutic vulnerability in targeting residual promoter-proximal TF function in ATRT.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 2. Tissue vs. CSF NGS in patients 24, 78, and 79.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 2. Tissue vs. CSF NGS in patients 24, 78, and 79.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Table 3. Representativeness of Study Participants.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Table 3. Representativeness of Study Participants.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 1. List of 152 genes on PredicineCARE panel.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 1. List of 152 genes on PredicineCARE panel.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Materials, including Figures/Figure legends S1-2 and note on Predicine CARE/CNB validation.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Materials, including Figures/Figure legends S1-2 and note on Predicine CARE/CNB validation.
- Open Access
- 23 December 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (5) , 881-889
Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.
- 23 December 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (5) , 881-889
Open AccessLongitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.
- 12 September 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (11) , 497-498
Teaching NeuroImage: Olfactory Stem Cell Injection Inducing Actively Secreting Respiratory Epithelium in a Cervical Syrinx
- 12 September 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (11) , 497-498
Teaching NeuroImage: Olfactory Stem Cell Injection Inducing Actively Secreting Respiratory Epithelium in a Cervical Syrinx
- 14 July 2022
- Published by Elsevier in World Neurosurgery
- Vol. 166, e475-e483
Streamlining the External Ventricular Drain and Intracranial Pressure Monitor Procedural Setup: A Quality Improvement Initiative
- 14 July 2022
- Published by Elsevier in World Neurosurgery
- Vol. 166, e475-e483
Streamlining the External Ventricular Drain and Intracranial Pressure Monitor Procedural Setup: A Quality Improvement Initiative
- Open Access
- 24 April 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 922
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma
High-grade gliomas (HGG) are devastating diseases in children and adults. In the pediatric population, diffuse midline gliomas (DMG) harboring H3K27 alterations are the most aggressive primary malignant brain tumors. With no effective therapies available, children typically succumb to disease within one year of diagnosis. In adults, glioblastoma (GBM) remains largely intractable, with a median survival of approximately 14 months despite standard clinical care of radiation and temozolomide. Therefore, effective therapies for these tumors remain one of the most urgent and unmet needs in modern medicine. Interleukin 13 receptor subunit alpha 2 (IL-13Rα2) is a cell-surface transmembrane protein upregulated in many HGGs, including DMG and adult GBM, posing a potentially promising therapeutic target for these tumors. In this study, we investigated the pharmacological effects of GB-13 (also known as IL13.E13K-PE4E), a novel peptide–toxin conjugate that contains a targeting moiety designed to bind IL-13Rα2 with high specificity and a point-mutant cytotoxic domain derived from Pseudomonas exotoxin A. Glioma cell lines demonstrated a spectrum of IL-13Rα2 expression at both the transcript and protein level. Anti-tumor effects of GB-13 strongly correlated with IL-13Rα2 expression and were reflected in apoptosis induction and decreased cell proliferation in vitro. Direct intratumoral administration of GB-13 via convection-enhanced delivery (CED) significantly decreased tumor burden and resulted in prolonged survival in IL-13Rα2-upregulated orthotopic xenograft models of HGG. In summary, administration of GB-13 demonstrated a promising pharmacological response in HGG models both in vitro and in vivo in a manner strongly associated with IL-13Rα2 expression, underscoring the potential of this IL-13Rα2-targeted therapy in a subset of HGG with increased IL-13Rα2 levels.
- 24 April 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 922
Open AccessIL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma
High-grade gliomas (HGG) are devastating diseases in children and adults. In the pediatric population, diffuse midline gliomas (DMG) harboring H3K27 alterations are the most aggressive primary malignant brain tumors. With no effective therapies available, children typically succumb to disease within one year of diagnosis. In adults, glioblastoma (GBM) remains largely intractable, with a median survival of approximately 14 months despite standard clinical care of radiation and temozolomide. Therefore, effective therapies for these tumors remain one of the most urgent and unmet needs in modern medicine. Interleukin 13 receptor subunit alpha 2 (IL-13Rα2) is a cell-surface transmembrane protein upregulated in many HGGs, including DMG and adult GBM, posing a potentially promising therapeutic target for these tumors. In this study, we investigated the pharmacological effects of GB-13 (also known as IL13.E13K-PE4E), a novel peptide–toxin conjugate that contains a targeting moiety designed to bind IL-13Rα2 with high specificity and a point-mutant cytotoxic domain derived from Pseudomonas exotoxin A. Glioma cell lines demonstrated a spectrum of IL-13Rα2 expression at both the transcript and protein level. Anti-tumor effects of GB-13 strongly correlated with IL-13Rα2 expression and were reflected in apoptosis induction and decreased cell proliferation in vitro. Direct intratumoral administration of GB-13 via convection-enhanced delivery (CED) significantly decreased tumor burden and resulted in prolonged survival in IL-13Rα2-upregulated orthotopic xenograft models of HGG. In summary, administration of GB-13 demonstrated a promising pharmacological response in HGG models both in vitro and in vivo in a manner strongly associated with IL-13Rα2 expression, underscoring the potential of this IL-13Rα2-targeted therapy in a subset of HGG with increased IL-13Rα2 levels.